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Abstract Defining permissive and non-permissive mis-
matches for transplantation is a demanding challenge. Single
mismatches at amino acid (AA) position 156 of human leuco-
cyte antigen (HLA) class I have been described to alter the
peptide motif, repertoire, or mode of peptide loading through
differential interaction with the peptide-loading complex.
Hence, a single mismatch can tip the balance and trigger an
immunological reaction. HLA-B*35 subtypes have been de-
scribed to evade the loading complex, 156 mismatch
distinguishing B*35:01 and B*35:08 changes the binding
groove sufficiently to alter the sequence features of the select-
ed peptide repertoire. To understand the functional influences
of residue 156 in B*35 variants, we analyzed the peptide
binding profiles of HLA-B*35:01156Leu, B*35:08156Arg and
B*35:62156Trp. The glycoprotein tapasin represents a target
for immune evasions and functions within the multimeric
peptide-loading complex to stabilize empty class I molecules
and promote acquisition of high-affinity peptides. All three
B*35 subtypes showed a tapasin-independent mode of pep-
tide acquisition. HLA-B*35-restricted peptides of low- and
high-binding affinities were recovered in the presence and
absence of tapasin and subsequently sequenced utilizing mass
spectrometry. The peptides derived from B*35 variants differ
substantially in their features dependent on their mode of re-
cruitment; all peptides were preferentially anchored by Pro at
p2 and Tyr, Phe, Leu, or Lys at pΩ. However, the Trp at
residue 156 altered the p2 motif to an Ala and restricted the
pΩ to a Trp. Our results highlight the importance of under-
standing the impact of key micropolymorphism and how a
single AA mismatch orchestrates the neighboring AAs.
Keywords HLA polymorphism . Peptide-loading complex .
Tapasin . Peptide-bindingmotif
Introduction
Hematopoietic stem cell transplantation (HSCT) is widely
used as a curative therapy for various hematological malig-
nancies and immune-related disorders (Blazar et al. 2012).
Human leucocyte antigens (HLAs) still remain the main bar-
rier for unrelated HSCT, since HLA molecules are character-
ized by an extensive genetic diversity (Robinson et al. 2015).
HLA molecules are scanning the intracellular proteomic con-
tent for peptides of self- or non-self origin, bind selected pep-
tides in the peptide-binding region (PBR), and present them to
the immune system. Most of the polymorphisms
distinguishing allelic variants are located in the PBR, deter-
mining the sequence of bound peptides. Every single peptide-
HLA complex displays a target for CD8+ immune effector
cells. It becomes obvious that a stringent HLA matching be-
tween donor and recipient is the most important criteria to be
considered in transplantation. It could be demonstrated that
best outcomes post-transplantation have been achieved using
HLA identical sibling donor:recipient pairs, whereas HLA
mismatching might lead to serious transplantation complica-
tions including graft-versus-host disease (GvHD), graft rejec-
tion, and/or mortality (Hauzenberger et al. 2008; Shaw 2008).
Rejection episodes occur when the transplanted donor-derived
T cells trigger allorecognition of incompatible recipient
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antigens following HSCT (Goker et al. 2001; Wood and
Goto 2012). The chance of finding an identical donor
for HSCT is still only 30 % in the Caucasian population
(Pidala et al. 2013); hence, in most cases, HLA-
mismatched transplants cannot be avoided. Thereby, it
is imperative to systematically analyze the differential
magnitude of mismatches between HLA subtypes to en-
able an intelligent mismatching.
Every single HLA-bound peptide alters the accessible sur-
face of the peptide-HLA complex (Burrows et al. 2007) that is
presented to immune effector cells; for that reason, the inves-
tigation of the individual peptide repertoire and allele-specific
peptide-binding profile is the first step to understand and pre-
dict histocompatibility. Here, the limiting factors for the selec-
tion of a given peptide from the intracellular proteomic pool
are (i) the interaction between the HLA and proteins of the
peptide-loading complex (PLC) and (ii) the amino acid (AA)
composition within the PBR, determining the sequence of a
bound peptide. Intracellular peptide loading onto HLA class I
molecules in the endoplasmic reticulum (ER) requires the
PLC, including the chaperone calreticulin (CRT), thiol-de-
pendent ERp57, transporter associated with antigen pro-
cessing (TAP), and the HLA class I-dedicated tapasin
(TPN) (Ackerman and Cresswell 2004; Wearsch and
Cresswell 2008).
TPN is an endoplasmic reticulum (ER) resident transmem-
brane glycoprotein that exists as a disulfide-linked heterodi-
mer with ERp57 (Dick et al. 2002) and acts in coordination
with other components of the PLC to mediate optimal peptide
loading, peptide editing, and preferential selection of stable
HLA class I complexes (Elliott and Williams 2005; Wearsch
and Cresswell 2007). Thus, peptide selection and loading with
the assistance of TPN results in the presentation of peptide-
HLA complexes with long half-life; most HLA allotypes are
highly dependent on TPN for peptide presentation. However,
few class I allotypes are able to load peptides independently of
TPN; TPN independency is conferred by distinct AA compo-
sitions within the HLA heavy chain (hc). A single mismatch at
a given position can induce TPN independency. Distinct HLA
class I alleles show a unique profile of TPN dependence for
peptide loading and cell surface expression, depending on the
nature of AAs located on certain polymorphic sites
within or outside the PBR (Badrinath et al. 2012; Park
et al. 2004). Studies revealed that mismatches located at
positions 114 (Park et al. 2003), 116 (Williams et al.
2002), or 156 (Badrinath et al. 2012) in the PBR sig-
nificantly impact the TPN dependency of certain HLA
class I molecules.
Micropolymorphism at residue 156 for HLA-B*44 sub-
types has been described to strongly impact on immune re-
sponses such as an alteration of the mode of peptide loading
(Badrinath et al. 2012), an alteration of the allele-specific pep-
tide repertoire (Fleischhauer et al. 1994), and/or the triggering
of T cell alloresponses (Badrinath et al. 2014; Keever et al.
1994). All of these immunological events have the potential to
cause graft rejection following HSCT (Fleischhauer
et al. 1990).
HLA-B*35 belongs to an allelic group with more than 180
alleles. HLA-B*35 molecules are expressed by approximately
20 % of Caucasians with the most frequent one being HLA-
B*35:01156Leu (9 % of Caucasians) (Marsh et al. 2000;
Ragupathi et al. 1995). Within the HLA-B*35 group, three
naturally occurring allotypes exhibit a single AA exchange
at position 156 (HLA-B*35:01156Leu, B*35:08156Arg, and
B*35:62156Trp). The allotypes HLA-B*35:01 and B*35:08
have been described to bind peptides of viral (human cyto-
megalovirus (HCMV) or Epstein-Barr virus (EBV)) origin;
the existence of T cells recognizing these pHLA-B*35 could
be verified indicating a role of this HLA subtypes in viral
immunity. Natural presentation of the described viral peptides
by HLA-B*35 alleles has not been observed, yet. However,
probable epitopes were mapped using various cell-based as-
says to demonstrate the function of T cells against the viral
pHLA-B*35 complexes (McAulay et al. 2009; Rickinson and
Moss 1997). Notably, even though B*35:01 and B*35:08 ex-
clusively differ at residue 156, both alleles bind different pep-
tides. The peptides that can trigger T cell responses when
bound t o HLA-B*35 : 01 i n c l ud e HCMV pp65
(IPSINVHHY) (Gavin et al. 1993), EBV EBNA1
(HPVGEADYFEY) (Liu et al. 2014), or EBV BZLF1
(LPEPLPQGQLTAY) (Tynan et al. 2005a). HLA-B*35:08
in complex with HCMV pp65 (CPSQEPMSTYVY) (Wynn
et al. 2008), HCMV pp65 (FPTKDVAL) (Wynn et al. 2008),
or EBV BZLF1 (LPEPLPQGQLTAY) (Tynan et al. 2005a)
elicit strong T cell responses similarly. The ability of these
HLA-B*35 alleles to trigger T cell responses when bound to
a viral peptide could be suggestive of their possible
roles in overcoming the dependence on the classical
HLA class I presentation pathway and thus viral im-
mune evasion strategies. In order to understand the
structural implication of the 156 mismatch for B*35:01
and B*35:08, crystal structures of HLA-B*35:01156Leu
and B*35:08156Arg bound to the same ligand have been
solved (Burrows et al. 2007; Green et al. 2004; Tynan
et al. 2005b). The distinct structural disparity of these
allelic mismatched variants explained their differential
peptide selection and consequently their immunogenic
incompatibility.
This study was carried out to investigate the func-
tional impact of micropolymorphism at position 156
for HLA*B35 subtypes. We utilized soluble HLA tech-
nology (Kunze-Schumacher et al. 2014) in order to an-
alyze the peptide-binding profiles of the three alleles
HLA-B*35:01156Leu, B*35:08156Arg, and B*35:62156Trp.
The knowledge of allele-specific peptide-binding motifs
and repertoires facilitates peptide prediction for
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The lymphoblastoid cell lines (LCLs) 721.220 (HLA−/
TPN−/TAP+), 721.221 (HLA−/TPN+/TAP+), and T2
(HLA+/TPN+/TAP−) were used for transduction of re-
combinant HLA-B*35/156 constructs. The cell lines
were maintained in RPMI 1640 medium (Lonza,
Verviers, Belgium) supplemented with 10 % heat-
inactivated fetal calf serum (FCS; Lonza, Verviers, Bel-
gium) and 200 mM glutamine (c.c.pro, Oberdorla, Ger-
many) . Human embryonic kidney 293 T cel ls
(HEK293T) were cultured in DMEM (Lonza, Verviers,
Belgium) supplemented with 10 % heat-inactivated FCS,
20 mM L-glutamine, 1 mg/ml penicillin-streptomycin
(c.c.pro, Oberdorla, Germany), and 1 mg/ml G418
(Gibco/Life Technologies GmbH, Darmstadt, Germany).
All cell lines were maintained at 37 °C in an atmo-
sphere of 5 % CO2.
Construction of lentiviral vectors
For expression of full length (m) HLA-B*35:01 (exons 1–7)
molecules, HLA-B*35:01+ cDNA was amplified by PCR
u s i n g t h e p r i m e r s H L A - B 1 - T A S ( 5 ′ -
GAGATGCGGGTCACGGCG-3′) and HLA-B-TAAS-E7
(5′-TCAAGCTGTGAGAGACACATCAG-3′). The PCR
produc t wa s c l oned in t o t h e l en t i v i r a l v ec t o r
pRRL.PPT.SF.pre.V5-His as previously described
(Badrinath et al. 2014). The vectors pRRL.mHLA-B*3508
and pRRL.mHLA-B*3562 were generated by site-directed
mutagenesis (SDM) using the primers Sdm_B3508_156_F
(5′-GTGGCGGAGCAGCGGAGAGCCTACC-3′) and
S d m _ B 3 5 0 8 _ 1 5 6 _ R ( 5 ′ - G G TA G G C T C T C
CGCTGCTCCGCCAC-3′) or Sdm_B3562_156_F (5′-
GTGGCGGAGCAGTGGAGAGCCTACCTG-3 ′) and
S d m _ B 3 5 6 2 _ 1 5 6 _ R ( 5 ′ - C A G G TA G G C
TCTCCACTGCTCCGCCAC-3′).
Vectors encoding for soluble (s)HLA-B*35/156 variants
were generated from pRRL.mHLA-B*35/156 vectors by in-
troducing a stop codon using the primers Sdm_B35_sE4_F
(5′-CCTCACCCTGAGATGAGAGCCATCTTCCCAGTC-
3 ′ ) a n d S dm _B 3 5 _ s E 4 _ R ( 5 ′ - G ACTGGGA
AGATGGCTCTCATCTCAGGGTGAGG-3′).
Verification of HLA-B*35/156 inserts was performed by
DNA sequencing using an ABI Prism 3730 DNA Analyzer
(Applied Biosystems GmbH, Darmstadt, Germany). Subse-
quently, endotoxin-free plasmid DNAwas purified using the
EndoFree® Plasmid Maxi Kit (Qiagen GmbH, Hilden,
Germany).
Recombinant eukaryotic cell lines
LCLs 721.220 and 721.221 or T2 cells were transduced with
lentiviral particles encoding for recombinant mHLA-B*35/
156 (exons 1–7) or sHLA-B*35/156 (exons 1–4) molecules
as described previously (Badrinath et al. 2012). Using Lipo-
fectamine® 2000 (Invitrogen/Life Technologies GmbH,
Darmstadt, Germany), HEK293T cells were transfected with
the plasmids encoding for mHLA-B*35/156 or sHLA-B*35/
156 for production of lentiviral particles. The target cells were
transduced with the respective lentivirus encoding for HLA-
B*35/156 constructs.
Surface expression of mHLA-B*35/156 molecules was an-
alyzed by flow cytometry using the antibodies anti-bw6-FITC
and W6/32-PE; data were acquired on a FACS Canto II
(Becton Dickinson GmbH, Heidelberg, Germany).
For quantitative verification of sHLA molecules in the su-
pernatant, a double-antibody sandwich (DAS)-ELISAwas ap-
plied. The mAb W6/32 was used as a capture antibody and a
rabbit anti-human β2m pab was utilized as the detection anti-
body. The clones with the highest expression of sHLA-B*35/
156 molecules were used for large-scale production.
Large-scale production of sHLA molecules and affinity
purification
sHLA-B35*/156 producing B-LCL cells were expanded in
the two-compartment bioreactor CELLine classic 1000. Su-
pernatants were harvested weekly and monitored for sHLA
production. sHLA molecules were affinity purified using N-
hydroxysuccinimide (NHS)-activated HiTrap columns
coupled to mAb W6/32. Affinity purification was performed
on the BioLogicDuoFlow system (Bio-Rad, Hercules, USA).
Trimeric complexes (class I hc, β2m, and peptide) were eluted
using 0.1 M glycine/HCl buffer (pH 2.7).
Mass spectrometric analysis of peptides
Following affinity purification, trimeric complexes were fil-
tered through an Amicon Ultra-15 Filter Unit (EMD
Millipore/Merck KgaA, Darmstadt, Germany) with a molec-
ular weight cutoff (MWCO) of 10 kDa and the peptides de-
tected in the flowthrough were considered to be of low-
binding (LB) affinity. The retentate was further acidified by
treatment with 0.1 % trifluoroacetic acid (TFA) and filtered
through a MWCO 10-kDa filter to elute high-binding (HB)
affinity peptides. Subsequently, the peptides were sequenced
using an Eksigent Nano-LC Ultra 2D HPLC coupled to LTQ
Orbitrap XL mass spectrometer (Thermo Fisher Scientific
GmbH, Schwerte, Germany). The mass spectrometric data
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were then utilized on Mascot server via a Mascot Daemon
interface (www.matrixscience.com). Database queries for
peptide sequences and peptide source were carried out by
Mascot software (Hirosawa et al. 1993) using the SwissProt
2012_11 human and the respective decoy databases.
UniProtKB/Swiss-Prot 2012_11 release of 28 November
2012 contains 538,585 sequence entries, comprising
191,240,774 AAs abstracted from 215,068 references
(http://www.uniprot.org).
Biophysical analysis of HLA-B*35/156 interactions
with PLC
Immunoprecipitation experiments were performed in order to
analyze the differential interaction of the HLA-B*35/156 hc
and distinct PLC components as previously described
(Badrinath et al. 2012). mHLA-B*35/156 expressing LCL
721.220 or LCL 721.221 cells were lysed for 30 min on ice
in Digitonin lysis buffer. The lysates were collected by centri-
fugation at 13,000 rpm for 15min at 4 °C and pre-cleared with
protein A-sepharose beads CL-4B for an hour. The lysates
were then added to protein A-sepharose beads covalently
coupled to rabbit anti-TAP1 pab to capture and immobilize
the immune complex on the beads. The immunoprecipitates
were analyzed bywestern blotting using antibodies against the
HLA-B hc and selected PLC components.
Computational analysis
In order to understand the structural implication of the
micropolymorphism at position 156 on HLA-B*35 mole-
cules, a computational simulationwas performed to artificially
exchange AAs at position 156. The structure of HLA-
B*35:01 (2AXG) (Tynan et al. 2005b) was overlaid with that
of B*35:08 (2AXF) (Tynan et al. 2005b), and a model of
B*35:62 was generated by mutation of Leu at 156
(B*35:01, 2AXG) to Trp using YASARA/FoldX software.
Results
Peptide recruitment and biophysical association
with the PLC
Flow cytometric analysis showed differential surface expres-
sion of mHLA-B*35/156 molecules on the surface of LCL
721.220 or 721.221 cells. The investigated B*35/156 variants
were able to load peptides independently of TPN; however,
the density of mHLA-B*35/156 molecules on the cell surface
is clearly influenced by the type of polymorphism at residue
156. The expression of mHLA-B*35:08 was found to be com-
paratively low in the absence of TPN compared to HLA-
B*35:01 and B*35:62 (Fig. 1a). These data illustrate that the
surface expression of HLA-B*35:08 is relatively more TPN
dependent than the surface expression of the other allelic var-
iants investigated. Results demonstrated that the surface ex-
pression of mHLA-B*35:62 was relatively more independent
of TAP compared to those of mHLA-B*35:01 and
B*35:08 (Fig. 1b).
The association of mHLA-B*35/156 molecules and TAP
could not be detected in TPN-deficient cells, indicating the
significance of TPN in bridging TAP and the HLA molecule.
However, a strong association of mHLA-B*35:01 and
B*35:08with TAPwas demonstrated in TPN-competent cells.
Surprisingly, no such interaction could be detected for mHLA-
B*35:62 (Fig. 2), indicating its complete PLC-independent
mode of peptide loading.
Peptide profiling
A total of 229, 261, or 492 peptides restricted to sHLA-
B*35:01, B*35:08, or B*35:62 are given in Table 1; peptide
sequences are given in Supplementary 1. Although an equal
concentration of purified sHLA-B*35/156 molecules was uti-
lized for mass spectrometric analysis of the bound peptides,
differential numbers of peptides could be recovered due to
differential pHLA complex stability among HLA-B*35/156
variants. A comparative analysis of HB and LB peptides fa-
cilitates the association of peptide-binding strength and dis-
tinct AA exchanges in the HLA hc. The individual profile of
peptides acquired in the presence or absence of TPN showed
relatively higher numbers of HB peptides for HLA-B*35:01
and B*35:08 (Fig. 3). In contrast, more LB peptides could be
recovered from sHLA-B*35:62 molecules in the presence or
absence of TPN.
Shared peptides
sHLA-B*35/156 variants were expressed in LCL 721.220 or
721.221 cells to ensure that the proteomic content is virtually
identical, with the major difference that in 721.220 cells, the
peptides are loaded without the assistance of TPN. However,
the HLA-B*35/156 allotypes were found to share a very small
subset of their overall peptide repertoire, both in the presence
and absence of TPN. Shared peptide analysis shows that 11
peptides (1.12 %) were shared among the HLA-B*35/156
variants (Fig. 4). More peptides were shared in the presence
of TPN than in its absence. Among these shared peptides, a
12-mer, ALSTGEKGFGYK (peptidyl-prolylcis-trans isomer-
ase A) was acquired in the absence of TPN, while 10 peptides
were acquired in the presence of TPN (Fig. 4b, c). The major-
ity of overall shared peptides associated with HLA-B*35:01
or HLA-B*35:08 were HB peptides (81.81 % for HLA-
B*35:01 and 63.63 % for HLA-B*35:08), while only
18.18 % of shared peptides associated with HLA-B*35:62
were found to be HB peptides (Supplementary 2).
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Only 3.72 % of the peptides were shared between
HLA-B*35:08 and HLA-B*35:62, while 7.77 % were
shared between HLA-B*35:01 and B*35:62. HLA-
B*35:01 and B*35:08 share an overall peptide repertoire
of 8.78 % (Fig. 4a). Between the three allelic variants, a
highly variable peptide repertoire could be observed; it
becomes obvious how the differential peptide-loading path-
ways lead to a divergent selection of the proteomic con-
tent. The differential association of the HLA-B*35 allelic
variants with the loading complex reflects on the peptide
selection. This is highlighted by the numbers of shared
peptides given in Fig. 4.
Characteristics of peptide anchor positions
Analysis of HLA-B*35/156-restricted peptides demonstrated
Pro at p2 (Fig. 5). The preference for Pro at p2 was decreased
for HLA-B*35:01-restricted LB peptides that were acquired
in the presence of TPN. HLA-B*35:08 and B*35:62 were
additionally anchored at p2 by Ala and Val. HLA-B*35:62-
restricted peptides that were acquired in the absence of TPN
were exclusively anchored by Ala at p2 (Fig. 5a).
At pΩ, a preference for Tyr, Phe, Leu, or Lys could
be observed (Fig. 5). Unlike HLA-B*35:01 and
B*35:08, B*35:62 preferentially demonstrated Trp at
pΩ when acquired in the absence of TPN. Approximate-
ly 50 % of sHLA-B*35:62-restricted HB peptides ac-
quired in the absence of TPN exhibited a preference
for Trp at pΩ (Supplementary 3). Furthermore,
13.13 % of sHLA-B*35:08-restricted HB peptides ac-
quired in the presence of TPN were preferentially an-
chored by Met at pΩ.
Length distribution of peptides
The majority of sHLA-B*35/156-restricted peptides were
found to be of canonical length (8–10 AAs). However, pep-
tides of non-canonical length (>10 AAs) could also be recov-
ered by sHLA-B*35/156 variants (Fig. 6). HLA-B*35:62, in
particular, was found to preferentially present peptides of non-
canonical length (48.83 and 50.85 % in the absence and pres-
ence of TPN, respectively). Among the peptides presented,
31.52 and 31.40 % non-canonical peptides were presented
by HLA-B*35:01 and B*35:08, respectively, in the absence
Fig. 1 mHLA-B*35/156 expression. Cells were analyzed for surface
expression of mHLA complexes using anti-bw6-FITC and anti-HLA-A/
B/C-PE (W6/32-PE) monoclonal antibodies. a Surface expression of
mHLA-B*35/156 variants on LCL 721.220 (HLA−/TPN−/TAP+) cells.
b Surface expression of mHLA-B*35/156 variants on T2 (HLA−/TPN+/
TAP−) cells. A higher amount of molecules could be detected for mHLA-
B*35:01 and B*35:62 on LCL 721.220 cells in comparison to the amount
of B*35:08 molecules. Results show relatively higher surface expression
of HLA-B*35:62 compared to B*35:01 and B*35:08 on T2 cells, thereby
indicating that the surface expression of B*35:62 is comparatively more
independent of TAP. Annotations: NC negative control (untransduced
cells)
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of TPN. In the presence of TPN, HLA-B*35:01 was
shown to present 40.15 % non-canonical peptides, while
HLA-B*35:08 was shown to present a lesser percentage
of longer peptides.
A significant percentage of HB peptides recovered from
HLA-B*35:01 or B*35:08, in the presence of TPN, was found
to be of canonical lengths (71.43 % for HLA-B*35:01 and
80.81 % for HLA-B*35:08); this is in contrast to HLA-
B*35:62-restricted peptides (28 %).
Taken together, in the absence of TPN, both canonical
and non-canonical sHLA-B*35/156-restricted HB peptides
were observed. The majority of HLA-B*35:01- and
B*35:08-restricted LB peptides were of canonical lengths.
Contrary, most of the HLA-B*35:62-restricted LB peptides
acquired in the absence of TPN were of non-canonical
length (71.79 %).
Molecular modeling
sHLA-B*35:62-restricted peptides that were acquired in the
absence of TPN are predominantly anchored by a C-terminal
Trp. Residue 156 that distinguishes the three allelic variants
is not part of pocket F and thus has no direct influence on
the peptide C-terminus. To understand the unexpected alter-
ation of the C-terminal peptide anchor, YASARA/FoldX
software was utilized for generating a model of HLA-
B*35:62. Crystal structures of HLA-B*35:01 (2AXG)
(Tynan et al. 2005b) and B*35:08 (2AXF) (Tynan et al.
2005b) are available and were overlayed. Since no structure
of HLA-B*35:62 is available, a model of HLA-B*35:62
was generated by mutating 156Leu in HLA-B*35:01 to
156Trp. In the HLA-B*35:62 model, the stacking arrange-
ment of 147Trp and 156Trp against 97Arg alters the F pock-
et indirectly and allows for a C-terminal Trp of the bound
peptides (Fig. 7).
Discussion
The degree of donor:recipient HLA-compatibility strongly in-
fluences clinical outcome after unrelated stem cell transplan-
tation. Considerable efforts have beenmade over the last years
to distinguish non-permissive HLA mismatches that
Fig. 2 Biophysical interaction of mHLA-B*35/156 with PLC
components. Cell lysates were used for immunoprecipitation with an
anti-TAP1 antibody. Protein-protein interactions were detected with anti-
bodies against HLA-B hc, CRT, ERp57, and TPN. a Detection of
CRT, ERp57, TPN, and HLA-B hc in TAP1-precipitates. b Lysate
controls showing levels of CRT, ERp57, TPN, and HLA-B hc in
untransduced and transduced LCL 721cells. The presence of essential
PLC components in the cells could be verified in the lysate controls. In
cells lacking TPN, an interaction between the HLA-B*35/156 hc and
TAP was not detected. In TPN-competent cells, hcs of HLA-B*35:01
or B*35:08 were strongly associated with TAP while no such
association could be demonstrated with B*35:62 hc
Table 1 Profile of peptides
HLA-B*35 allele HB/LB peptides Peptides (N)
B*35:01 (TPN−) LB 38
HB 54
B*35:01 (TPN+) LB 46
HB 91
B*35:08 (TPN−) LB 33
HB 53
B*35:08 (TPN+) LB 76
HB 99
B*35:62 (TPN−) LB 117
HB 139
B*35:62 (TPN+) LB 136
HB 100
This table shows the overall profile of LB or HB peptides
LB low-binding peptides, HB high-binding peptides, TPN+ acquired in
the presence of TPN, TPN− acquired in the absence of TPN, N number of
peptides
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dramatically increase the risk of post-transplantation out-
comes from permissive HLA mismatches (Bacigalupo 2013;
Flomenberg et al. 2004). Understanding the impact of a par-
ticular key polymorphism on the mode of peptide loading, the
repertoire of selected and presented peptides, and consequent-
ly the alteration in pHLA landscapes and half-life is the pre-
requisite for the estimation of mismatch allogenicity when no
clinical data are available.
Fig. 3 Differential stability of sHLA-B*35/156 molecules. The x axis
represents the HLA-B*35 subtypes, while the y axis represents
percentage prevalence of LB and HB peptides. Dark grey represents the
LB peptides and light grey the HB peptides. a Analysis of total LB and
HB peptides acquired in LCL 721.220 cells. b Analysis of total LB and
HB peptides acquired in LCL 721.221 cells. sHLA-B*35:62 molecules
derived from LCL 721.221 cells showed a higher appearance (57.63 %)
of LB than HB peptides. In contrast, sHLA-B*35:01/35:08 molecules
revealed the presentation of comparatively higher percentages of HB
peptides than LB peptides
Fig. 4 Shared peptides of sHLA-
B*35/156 variants. a Overall
shared peptide repertoire of HLA-
B*35:01, B*35:08, or B*35:62
restricted peptides. b Shared
peptides acquired in the absence
of TPN. c Shared peptides
acquired in the presence of TPN.
A small percentage (1.12 %) of
the overall peptide repertoire was
found to be shared between the
three different allotypes. Among
the pool of peptides, 0.23 and
1.82 % of eluted peptides were
shared in the absence and
presence of TPN, respectively
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Fig. 5 p2 and pΩ anchor
positions of sHLA-B*35/156-
restricted peptides. Characters in
red represent the predominant
AAs occurring at major anchor
position (frequencies >25%). The
dots indicate the variable number
of AA residues. The graphs on
the right panel indicate the
frequencies of AAs. The x axis
represents the AA residues at p2
and pΩ. The y axis represents the
percentage prevalence of
individual AAs. Black, grey, or
crossed bars represent the alleles
HLA-B*35:01, B*35:08, or
B*35:62. a Peptide anchor motif
in the absence of TPN. b Peptide
anchor motif in the presence of
TPN. Pro was the most frequently
occurring AA at p2 position. All
HLA-B*35/156 variants are
predominantly anchored by Tyr,
Phe, Leu, or Lys at pΩ. However,
HLA-B*35:62 is preferentially
anchored byAla at p2 and Trp at p
Ω in the absence of TPN
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The loading of peptides onto HLA class I molecules is a
complex procedure and facilitated by the PLC, wherein TAP
and TPN are essential components. TPN supports peptide
loading, stabilizes the TAP complex, and thus indirectly pro-
motes the accessibility of peptides in the ER (Garbi et al.
2003). Furthermore, TPN is known to function in peptide
editing and loading of high-affinity peptides (Barnden et al.
2000;Williams et al. 2002). In the absence of TPN, interaction
of class I molecules to TAP is disrupted, resulting in unstable
pHLA complexes (Peh et al. 2000). Most of the HLA class I
molecules rely strictly on the functions of TPN and TAP for
efficient peptide loading. Certain viral proteins and cancer
proteins target these PLC components to prevent the presen-
tation of immunogenic peptides and recognition by cytotoxic
CD8+ T cells. Nevertheless, recent studies document host
strategies to circumvent these immune evasions by choosing
pathways (Boyle et al. 2013; Fromm et al. 2002; Lautscham
et al. 2003) that could operate independent of these PLC com-
ponents. Certain allelic HLA class I variants that load peptides
independently from TPN and/or TAP are therefore still able to
present a fraction of the intracellular peptide repertoire to the
immune system. However, TPN- or TAP-independent peptide
presentation might lead to a differential peptide repertoire that
would be selected and subsequently presented, since those
peptides are not optimized for stabilizing the respective
HLA allele. HLA class I variants that are TPN- and/or TAP-
a b
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Fig. 6 Length distribution of sHLA-B*35/156-restricted peptides.
Peptide length (AA) is given on the x axis, and the percentage
prevalence of peptides is given on the y axis. Black, grey, or crossed
bars represent the alleles HLA-B*35:01, B*35:08, or B*35:62. a, b
Length distribution of LB peptides. c, d Length distribution of HB
peptides. In the presence of TPN, the majority of HLA-B*35:01- and
B*35:08-restricted HB peptides were of canonical length. HLA-
B*35:62-restricted LB peptides that were acquired in the absence of
TPN were of non-canonical length
Fig. 7 Model of HLA-B*35:62. Molecular modeling of position 156 in
HLA-B*35 utilizing YASARA/FoldX software. Structural overlay of
HLA-B*35:01 and B*35:08 both bound to a decamer peptide
(APQPAPENAY) and the modeled structure of HLA-B*35:62. PDB,
2AXG (Tynan et al. 2005b) and 2AXF (Tynan et al. 2005b)
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independent differ from the PLC-dependent alleles often ex-
clusively by one AA difference (Badrinath et al. 2012; Neisig
et al. 1996; Williams et al. 2002). Understanding the effect of
polymorphism on the immune function of a given HLA mol-
ecule can only take the form of a measure of histocompatibil-
ity. The similarity of allele peptide-binding profiles and reper-
toires is such a measure.
HLA-B*35:01 and B*35:08 can be distinguished by a
micropolymorphism at position 156; both variants are de-
scribed to present viral peptides (Liu et al. 2014; Tynan et al.
2005a, 2007; Wynn et al. 2008), suggesting a PLC indepen-
dency for these allelic variants. This study was focused on
determining the mode of antigen recruitment utilized by nat-
ural occurring HLA-B*35 allotypes that differ at one single
mismatch at residue 156, HLA-B*35:01156Leu, B*35:08156Arg,
and B*35:62156Trp.
All three HLA-B*35/156 variants studied were expressed
on the cell surface of TPN-deficient cells, suggesting a TPN-
independent mode of peptide acquisition and presentation for
these molecules. However, the spectrum of TPN dependence
among these allotypes was found to vary with the nature of
AA at position 156. The data revealed the influence of
microploymorphism at position 156 on the molecule
expression levels and stability of pHLA complexes on the
cell surface. A recent study by Rizvi et al. (2014) also dem-
onstrated a TPN-independent mode of peptide loading for
HLA-B*35:01. The 156 micropolymorphism distinguishing
the HLA-B*35/156 allotypes causes a functional disparity
for their TPN interaction. Unlike HLA-B*35:01156Leu and
B*35:62156Trp, surface expression of B*35:08156Arg was de-
creased by more than twofold in the absence of TPN, indicat-
ing partial dependence of B*35:08 on TPN for peptide loading
and presentation. In addition to TPN independence, our results
showed that the surface expression of HLA-B*35:62 was rel-
atively independent of TAP compared to that of HLA-
B*35:01 and B*35:08.
Immunoprecipitation experiments demonstrated differen-
tial association of TAP with the HLA-B*35:01156Leu hc,
B*35:08156Arg hc, or the B*35:62156Trp hc. The HLA-B*35/
156 hc could not be detected in any of the TAP complexes
from cells lacking TPN (LCL 721.220 cells), since the asso-
ciation between TAP and the HLA hc is mediated through
TPN. TPN plays an important role in steady state expression
of TAP (Lehner et al. 1998) and also helps in the stabilization
of the heterodimeric TAP1/TAP2 complex. In contrast, in
TPN positive cells (LCL 721.221), a strong association of
both HLA-B*35:01 hc and HLA-B*35:08 hc with TAP could
be detected. The observations validate the accepted role of
TPN in bridging a HLA class I molecule and the TAP complex
(Ortmann et al. 1997; Sadasivan et al. 1996). However, unlike
HLA-B*35:01 and B*35:08, the association of the B*35:62
hc with TAP could not be confirmed. This result could mean
that either HLA-B*35:62 does not incorporate into the PLC
and does not utilize the TAP complex for peptide loading or
the transit period of HLA-B*35:62 into the PLC is so concise
that the interaction could not be detected using this experi-
mental approach.
The results from the immunoprecipitation experiments
were in synchrony with the flow cytometric studies where
the surface expression of HLA-B*35:62 was found to be com-
paratively independent of TAP. The observed results could be
suggestive that HLA-B*35:62 might be very weakly or not at
all associated with TAP. The findings postulate the involve-
ment of an unknown alternate pathway for peptide selection
and presentation by HLA-B*35:62. Given that all the three
HLA-B*35/156 variants share the same AA sequence except
for the single AA polymorphism at position 156, Trp156 in
HLA-B*35:62 would be the most likely factor regulating the
association of this allele with TAP and modulating a differen-
tial mode of peptide loading. Several studies revealed how
certain allelic variants that differ at one or more AAs might
vary in their TAP association. HLA-B*44:02116Asp/156Asp
which differs from HLA-B*44:03116Asp/156Leu by a single
AA at position 156 and from HLA-B*44:05116Tyr/156Asp at
position 116 bounds strongly to TAP, while HLA-
B*44:03116Asp/156Leu (Neisig et al. 1996) and HLA-
B*44:05116Tyr/156Asp (Zernich et al. 2004) did not. It was dem-
onstrated that HLA-A*68:07116His/70Gln is associated much
stronger with TAP than HLA-A*68:03116Asp/70His (Turnquist
et al. 2002). In 1996, Neisig et al. (1996) demonstrated that
HLA-B alleles with aromatic AAs at position 116 could be a
better TAP binder compared to the others. It was observed that
among the HLA-B*15 allotypes, HLA-B*15:10116Tyr showed
a stronger association with TAP compared to HLA-
B*15:18116Ser (Turnquist et al. 2000). In case of HLA-
B*35:62156Trp, it is possible that Trp at position 156 alters
the overall conformation of the PBR sufficiently to affect its
interaction with neighboring AA residues, thereby rendering a
TAP-independent mode of peptide loading.
To analyze if the polymorphic difference at position 156
alters the peptide-binding specificities, soluble HLA technol-
ogy (Bade-Doeding et al. 2004; Kunze-Schumacher et al.
2014) was utilized to characterize the repertoire of peptides
presented by HLA-B*35:01156Leu, B*35:08156Arg, and
B*35:62156Trp. In the present study, it could be demonstrated
how a single mismatch at residue 156 in HLA-B*35/156 al-
lotypes changes the peptide-binding groove sufficiently to al-
ter the features of the selected peptide repertoire.
Position p2 and the C-terminal position pΩ of a peptide are
significant for an effective binding in the PBR of most allo-
types (Falk et al. 1991; Parker et al. 1992) and thus determine
allelic specificity. Hence, the HLA-B*35/156-bound peptides
were investigated for the peptide-binding anchor motifs at p2
and pΩ. The results demonstrated similar peptide-binding
preferences for HLA-B*35:01 and B*35:08; however, HLA-
B*35:62 showed striking differences for the anchor motif at
256 Immunogenetics (2016) 68:247–260
p2 and pΩ, especially in TPN-deficient cells. The mass spec-
trometric analysis revealed that HLA-B*35:01- and B*35:08-
restricted peptides acquired in the presence or absence of TPN
are preferentially N-terminal anchored by Pro at p2. The pref-
erence for Pro at p2 for HLA-B*35:01 and B*35:08 is con-
sistent with previous studies (Escobar et al. 2008; Falk et al.
1993; Sidney et al. 1995; Steinle et al. 1995). In contrast,
surprisingly, the binding motif of HLA-B*35:62 showed an
unusual preference for Ala at p2, in the absence of TPN.
Comparison of AA frequencies in peptides derived from
sHLA-B*35/156 showed a preference of Tyr, Phe, Leu, or
Lys at pΩ. Unlike HLA-B*35:01 and B*35:08, B*35:62 pref-
erentially binds peptides with Trp at pΩ in the absence of
TPN. These results imply the influence of Trp at position
156 in HLA-B*35:62 on alteration of peptide selectivity by
TPN. To validate the possible structural implication of posi-
tion 156 on HLA-B*35:62 molecule, a structural model of
HLA-B*35:62 was generated by mutating Leu at position
156 in the HLA-B*35:01 structure (2AXG) (Tynan et al.
2005b) to Trp. This mutational model of HLA-B*35.62 re-
vealed a stacking arrangement of 147Trp and 156Trp against
97Arg. The residue triad, 147Trp/156Trp/97Arg, was found to
be highly selective for a C-terminal Trp of the bound peptide.
It was also demonstrated that HLA-B*35/156 variants were
able to present peptides of non-canonical lengths (>10 AAs).
Generally, it was considered that HLA class I molecules pres-
ent peptides of canonical length (8–10 AAs). The limit for
peptide length restriction depends, in part, by structure and
conformation of PBR. It was reported that peptides of non-
canonical length could be bound by HLA-B*35:01 and
B*35:08 molecules and such peptides can be highly immuno-
genic (Green et al. 2004; Probst-Kepper et al. 2004; Tynan
et al. 2005a).
Furthermore, to understand if the micropolymorphism at
position 156 would impact the stability of pHLA complexes,
peptide binding affinities, as reflected by profiles of LB and
HB peptides, were analyzed and correlated with the results of
flow cytometry and immunoprecipitation experiments. Anal-
ysis of peptides presented by HLA-B*35:01 and B*35:08
molecules in the presence of TPN (LCL 721.221 cells)
displayed the majority of them being HB peptides. It was
expected that the absence of TPN would lead to the presenta-
tion of a higher quantity of LB peptides. However, no signif-
icant differences between the percentages of HB and LB pep-
tides were observed from peptides presented by these alleles
in the absence of TPN. Especially, it was expected that HLA-
B*35:08, which was found to be relatively more dependent on
TPN for surface expression, would present peptides of low
affinity in the absence of TPN. Our findings suggests that
the probable dependence of HLA-B*35:08 on TPN is on
egress of pHLA complex from ER to cell surface and their
stabilization on cell surface rather than inside the cell. The
results could be comparable to the findings observed in
peptides associated with HLA-B*08:01 and HLA-A*02:01,
where the peptides acquired in absence of TPN were found
to be of unexpected higher affinity than those acquired in its
presence (Zarling et al. 2003). Moreover, Raghuraman et al.
(2002), using an insect cell-reconstituted system and peptide
translocation assay, observed that TPN does not alter the pep-
tide translocation efficiency and presence of TPN unexpect-
edly slightly reduced the affinity of TAP complexes for pep-
tides, suggesting that TPN is less likely to alter the peptide
selectivity by TAP and hence the features of TAP-
translocatable peptides. These results indicated the role of
TPN in stabilizing a peptide receptive conformation of the
PBR but not to function as a peptide editor to discriminate
between low- and high-binding peptides. Furthermore, a pep-
tide receptive conformation of the PBR may not always mean
the conformation of HLAmolecule with HB affinity or tightly
bound peptides.
Beside this, HLA-B*35:62 was shown to present a higher
percentage of LB peptides in the presence of TPN that could
be indirectly attributed to its TAP-independent character. The
selectivity of TAP is important because it helps in peptide
selection by translocation of peptides of optimal length and
sequence to their corresponding HLA class I molecules
(Momburg et al. 1994a, b). Our experimental data revealed
that HLA-B*35:62 could acquire peptides independent of
TAP. It is most likely that TAP is not being utilized for selec-
tion of HLA-B*35:62-specific peptides; therefore poorly se-
lected peptides are presented by B*35:62 even in the presence
of TPN. All these observations imply that the AAmismatch at
position 156 in HLA-B*35 variants has the potential to alter
the stability of these pHLA complexes and influence the mode
by which TPN or TAP functions.
The peptide-binding characteristics of individual HLA
class I proteins are shown to be a major factor determining
the immunorecognition of pathogens (Pereyra et al. 2010) and
the findings for these HLA-B*35/156 alleles indicate a prob-
able role in the presentation of viral epitopes. Moreover,
refolding assays on conformational stabilities have shown that
TPN-independent allotypes were found to be more assembly
competent and are in a more stable peptide-receptive confor-
mation compared with TPN-dependent allotypes (Geironson
et al. 2013; Rizvi et al. 2014). This result highlighted the
added advantage of these TPN-independent alleles for patho-
gen recognition. Paradoxically, dependence of individual
HLA class I molecules on TPN can influence the assembly
and stability of individual HLA class I molecules and have a
subsequent impact on disease progression (Rizvi et al. 2014).
Moreover, the presence of Trp at position 156 in HLA-
B*35:62 was shown to confer a TAP-independent mode of
peptide loading that could be suggestive of conferring the
ability of peptide presentation via non-classical pathways
and its potential role in immune response against viral infec-
tions. However, such differences on the mode of peptide
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loading can have interference on the alliance with ER quality
control factors, stabilities of antigenic peptide associations
with HLA-B molecules, and hence the abilities of HLA-B
molecules to mediate immune responses during infections.
HLA-B*35:62 is a rare allele occurring sparsely in Hispanic
population (http://www.allelefrequencies.net; http://www.ebi.
ac.uk) and further studies are needed to better understand the
reason for its failure to be selected in the course of host-
pathogen co-evolution.
Our study highlights how a single AAmismatch at position
156 orchestrates the mode of peptide loading and repertoire of
presented peptides. This study as a whole is a part of our
continual effort to provide better explanation and estimation
of outcomes of HLA mismatches through biochemical and
structural analyses of key polymorphic position in HLA al-
leles. These results will direct toward intelligent mismatching
strategies and guide toward personalized treatment of viral
infections.
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